In support of this point, the expression of PGC-1α and that of the glutamine pathway are positively correlated in ERBB2+ breast cancer patients, and high expression of glutamine metabolism enzymes is associated with shorter survival. The gene discussed is PPARGC1A; the disease is breast carcinoma.